We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Illumina Acquires Advanced Liquid Logic as Key Component for Next-Generation Genomic Solutions

By LabMedica International staff writers
Posted on 29 Jul 2013
Illumina, Inc. More...
(San Diego, CA, USA) has announced its acquisition of Advanced Liquid Logic (ALL; Research Triangle Park, NC, USA), a leading provider of liquid handling solutions. ALL, now a wholly owned subsidiary of Illumina, has developed a proprietary “digital microfluidics” technology based on electrowetting that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols. This technology will be used to enable Illumina to deliver a highly efficient sample-to-answer next-generation sequencing (NGS) workflow to advance diagnostic and research genomics.

“For our research customers, ALL’s technology will further streamline the industry's simplest NGS workflow, while for clinical and applied markets, where ease of use and consistency are especially valued, it will allow us to offer integrated, end-to-end solutions,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions business; “ALL brings an impressive IP portfolio in digital microfluidics and a talented team with a track record of innovation.”

One of Illumina's goals is to provide customers with a holistic set of tools to quickly and easily go from biological sample to answer, minimizing the risk of errors, and reducing hands-on time in the lab. To that end, Illumina announced it is collaborating with leading vendors of liquid handling robotic platforms to make automation solutions for high-throughput sample preparation more accessible. With its acquisition of ALL, Illumina will be able to introduce similar benefits to its low- and mid-throughput customers. ALL’s versatile technology has been demonstrated across numerous applications, including nucleic acid isolation from various sample types and library generation for NGS. Its robust solution has an advantage in precisely handling low sample volumes, an increasingly important focus for clinical and research laboratories.

Related Links:

Illumina, Inc.
Advanced Liquid Logic
ALL’s technology



Gold Member
Serological Pipets
INTEGRA Serological Pipets
Collection and Transport System
PurSafe Plus®
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.